Galapagos Presents Favorable Phase 1 Data for IBD Target
News Oct 21, 2014
The oral presentation entitled, “GPR84, a novel target for the development of therapies in IBD,” (abstract OP183), will take place in the Free Paper Session “Towards better understanding of IBD pathogenesis,” at 12.00 PM in Hall N on 21 October, 2014. Galapagos will present compelling pre-clinical evidence for GPR84 playing a key role in IBD pathology. The discovery of a selective antagonist of GPR84 led to GLPG1205, which shows strong efficacy in relevant pre-clinical models for IBD.
Galapagos will also present a poster on the safety and druglike properties of GLPG1205 in clinical Phase 1: “Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD,” (P0341), today in Hall XL from 9.00 – 17.00. GLPG1205 was shown to be safe and generally well tolerated in healthy volunteers up to 100 mg daily. The drug shows a favorable PK/PD profile, clearly demonstrating the ability of the compound to engage GPR84. Once-daily dosing of GLPG1205 resulted in a sustained and extensive full 24-hour inhibition of GPR84 ligand binding.
Both the slides and poster are available on www.glpg.com.
In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs. These programs include novel targets for inflammatory disorders that were identified and validated by Galapagos using its proprietary target discovery engine. Subsequent Galapagos research led to the discovery of novel compounds acting on those targets. Galapagos is responsible for execution of Phase 1 and Phase 2A studies with compounds in the alliance.
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
The heart is the first organ to develop in the womb and the first cause of concern for many parents. Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby."We can try to rebuild the shape of the early development heart in the lab," said Professor Zhen Ma. "It mimics the very early stage, during the embryo genesis - how the heart was formed."READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018